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 Background Data from observational studies suggest that body mass index (BMI) is causally related to esophageal adenocar-
cinoma (EAC) and its precursor, Barrett’s esophagus (BE). However, the relationships may be affected by bias and 
confounding.
 Methods We used data from the Barrett’s and Esophageal Adenocarcinoma Genetic Susceptibility Study: 999 patients with 
EAC, 2061 patients with BE, and 2169 population controls. We applied the two-stage control function instrumental 
variable method of the Mendelian randomization approach to estimate the unbiased, unconfounded effect of BMI 
on risk of EAC and BE. This was performed using a genetic risk score, derived from 29 genetic variants shown to 
be associated with BMI, as an instrument for lifetime BMI. A higher score indicates propensity to obesity. All tests 
were two-sided.
 Results The genetic risk score was not associated with potential confounders, including gastroesophageal reflux symp-
toms and smoking. In the instrumental variable analyses (IV), EAC risk increased by 16% (IV-odds ratio [OR] = 1.16, 
95% confidence interval [CI] = 1.01 to 1.33) and BE risk increased by 12% (IV-OR = 1.12, 95% CI = 1.00 to 1.25) per 
1 kg/m2 increase in BMI. BMI was statistically significantly associated with EAC and BE in conventional epidemio-
logic analyses.
 Conclusions People with a high genetic propensity to obesity have higher risks of esophageal metaplasia and neoplasia than 
people with low genetic propensity. These analyses provide the strongest evidence to date that obesity is inde-
pendently associated with BE and EAC, and is not due to confounding or bias inherent in conventional epidemio-
logic analyses.
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Esophageal adenocarcinoma (EAC) incidence continues to rise in 
industrialized nations (1,2). Of the estimated 17 460 people newly 
diagnosed with esophageal cancer in the US in 2012 (3), over 
11 000 were diagnosed with EAC (4), and the majority will not sur-
vive for more than one year (5).
Most EAC cases arise within Barrett’s esophagus (BE), a meta-
plastic transformation of the esophageal lining associated with 
gastroesophageal reflux (GER) (6), and both EAC and BE are sub-
stantially more common in white men (7,8). Extensive epidemio-
logical research has shown that obesity increases the risk of EAC 
and BE (in particular, abdominal obesity) (9,10), such that trends 
of increasing prevalence of obesity may explain part of the contin-
ued rise in EAC incidence (11). If the associations were shown to 
be causal, then obesity would be a key target for primary preven-
tion of EAC. However, given the many environmental, dietary and 
other risk factors associated with obesity, it is difficult to exclude 
other explanations for the associations observed in these studies, 
such as confounding by such factors or biased recall by study 
participants.
“Mendelian randomization” is one approach to exploring the 
possible causal nature of the observed associations between obesity 
and risk of EAC and BE (12). This approach uses instrumental vari-
ables (eg, genetic variants that proxy for directly measured envi-
ronmental factors) to make causal inferences about the relationship 
between a risk factor and an outcome; results from this method are 
considered to be analogous to the outcomes of a randomized trial 
(12–14). For BMI and EAC, inheriting an allele associated with 
higher BMI (eg, each A allele of the fat mass and obesity-associated 
protein [FTO] rs1558902 polymorphism) (15) is akin to being ran-
domly allocated a higher BMI (eg, 0.39 kg/m2 higher for each addi-
tional risk allele in FTO) than individuals with other genotypes 
(eg, TT genotype of rs1558902). If obesity is causally related to 
EAC, then the variability in BMI that is because of genotype should 
confer differences in EAC risk directly attributable to obesity. 
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Importantly, the instrumental variable approach overcomes issues 
of confounding and recall bias inherent in observational studies. 
First, since alleles are randomly allocated from parents to offspring 
at conception, the association between genotype and outcome is 
not confounded by environmental exposures (12,13,16). Second, 
genetic variants are measured reliably and are not affected by dis-
ease status (17). Further, as those with the risk allele have been 
essentially allocated randomly to higher levels of exposure across 
the lifecourse, genetic variation may more accurately reflect life-
time exposure compared with a single measurement (12,13,18).
Most phenotypes are due to the effects of multiple genes; how-
ever, the same principles apply. Using multiple genetic variants as 
instrumental variables can actually increase statistical power and 
improve the precision of causal estimates (19). Here, we report the 
findings of a Mendelian randomization study that used data and 
genetic material from the Barrett’s and Esophageal Adenocarcinoma 
Genetic Susceptibility Study (BEAGESS) and instrumental variable 
methods (13,16). We used multiple genetic variants that have been 
robustly associated with BMI in genome-wide association studies 
(GWAS) (15) as instrumental variables to reassess the observational 
estimates of the effect for obesity on EAC and BE.
Methods
The BEAGESS study included a subset of ethnically homogenous 
individuals of European ancestry from 14 epidemiological studies 
conducted in Western Europe, Australia, and North America by 
investigators in BEAGESS (Supplementary Table  1, available 
online). European ancestry was confirmed in GWAS samples 
using principal components analysis. The design of the BEAGESS 
study has been described in detail previously (20). The study was 
approved by the institutional review boards or research ethics com-
mittees of each participating institution.
We calculated BMI as weight divided by height squared (kg/
m2). While the individual studies captured participants’ weight at 
various periods of life (9), for the current analysis we selected the 
weight from each study that most accurately reflected usual adult 
weight prior to any disease-related weight loss. Genotype informa-
tion was available for 29 of the 32 genetic variants (using either the 
directly genotyped single nucleotide polymorphism [SNP] or “LD 
proxy” SNPs with r2 greater than 0.80 identified using HapMap) 
determined by the Genetic Investigation of Anthropometric Trials 
(GIANT) Consortium as being robustly associated with BMI in 
European populations (Table  1) (15). Genotyping of DNA from 
buffy coat or whole blood was performed using the Illumina 
HumanOmni1-Quad platform as previously described (20). Call 
rates were greater than or equal to 95%, and all SNPs were in 
Hardy-Weinberg equilibrium over controls given α = 0.0001.
A total of 1516 EAC and 2416 BE case patients, and 2187 popula-
tion controls had DNA available for genome-wide genotyping. Of 
these, 517 EAC, 355 BE, and 18 controls had missing data on weight 
and/or height and were excluded from this analysis. Of the 5229 
Table 1. Single nucleotide polymorphisms included in the genetic risk score for body mass index
Chr Nearest gene SNP Risk allele* Other allele Frequency of risk allele Per allele change in BMI†
1 NEGR1 rs2815752 T C 0.62 0.13
TNNI3K rs1514175 A G 0.43 0.07
PTBP2 rs10489741 T C 0.58 0.06
SEC16B rs543874 G A 0.20 0.22
2 TMEM18 rs2867125 C T 0.82 0.31
ADCY3, RBJ rs713587 A G 0.49 0.14
FANCL rs2192497 G A 0.29 0.10
3 CADM2 rs13078807 C T 0.22 0.10
4 GNPDA2 rs10938397 G A 0.43 0.18
SLC39A8 rs13107325 A G 0.08 0.19
5 FLJ35779 rs10057967 A G 0.64 0.10
ZNF608 rs4836133 A G 0.43 0.07
6 TFAP2B rs987237 C T 0.19 0.13
NUDT3 rs206936 C T 0.19 0.06
9 LRRN6C rs10968576 G A 0.32 0.11
11 STK33, RPL27A rs11041994 C A 0.52 0.06
BDNF rs7103411 T C 0.77 0.19
CELF1, MTCH2 rs7124681 T G 0.41 0.06
12 BCDIN3D, FAIM2 rs7138803 A G 0.39 0.12
13 MTIF3, GTF3A rs9512699 G A 0.20 0.09
14 NRXN3 rs17109256 T C 0.22 0.13
15 MAP2K5 rs2241423 C T 0.79 0.13
16 GPRC5B, IQCK rs12444979 G A 0.86 0.17
SH2B1 rs7498665 C T 0.40 0.15
FTO rs9930506 G A 0.42 0.39
18 MC4R rs571312 T G 0.23 0.23
19 KCTD15 rs29942 G A 0.68 0.06
QPCTL rs2287019 C T 0.80 0.15
ZC3H4, TMEM160 rs3810291 T C 0.66 0.09
* BMI-increasing risk allele. BMI = body mass index; SNP = single nucleotide polymorphism.
†  The increase in kg/m2 per one additional BMI-increasing risk allele. From reference 15.
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participants with BMI data (999 EAC, 2061 BE, and 2169 controls), 
5158 had complete genotype data on all 29 SNPs and 71 had geno-
type data on at least 27 SNPs (70 had missing data on one SNP, one 
had missing data on two SNPs); we imputed genotype data on those 
71 participants with missing SNP data using mean replacement.
We created a genetic risk score (GRS) from the 29 SNPs to be 
an instrumental variable for BMI. The GIANT GWAS found no 
evidence of nonadditive effects among the 29 SNPs (15), thus we fit 
additive SNP effects. For each SNP, participants received a score of 
0, 1, or 2 for carrying zero (wild-type homozygous), one (heterozy-
gous) or two (homozygous for the risk allele) BMI-increasing risk 
alleles, respectively. Imputed SNPs had values that ranged from 0 to 
2. The GRS was then calculated by summing across all SNPs (the 
GRS could theoretically range from 0 to 58). We also constructed 
a weighted GRS, where the BMI-increasing alleles for each SNP 
were weighted by the per allele change in BMI (the increase in kg/
m2 per one additional risk allele) reported for the SNP or its LD 
proxy-SNP in the GIANT BMI GWAS (the weighted GRS could 
theoretically range from 0 to 7.98) (15).
Other covariates included in analyses were age (years, continu-
ous), sex, education (less than high school, high school, or more), 
pack-years of smoking (never smoker, ≤15, 15.01–30, 30.01–50, 
and >50 pack-years derived from dividing the number of ciga-
rettes smoked by 20 and multiplying by the total number of years 
smoked), regular alcohol consumption (yes/no), GER (never/ever), 
and use of nonsteroidal anti-inflammatory drugs (NSAIDs, never/
ever), and acid suppressant medications (never/ever). We included 
participants with missing data for covariates in the analyses using 
an additional category for missing values.
Statistical Methods
Analyses were performed separately for EAC and BE. As the rela-
tionships between BMI and risks of EAC and BE are linear (9,10), 
we fit models with BMI as a continuous variable and computed 
odds ratios (OR) per 1 kg/m2 increase in BMI. We examined the 
associations between potential confounders and case-control sta-
tus using chi-square tests and Student t-tests. In control patients, 
the associations between potential confounders, the GRS, and BMI 
were assessed using linear regression, Student t-test, and analysis 
of variance.
For the instrumental variable analysis, we used the two-stage 
control function instrumental variable approach (21), with the 
GRS as an instrumental variable, and assumed an additive model. 
The first-stage linear regression analysis was restricted to control 
patients for the purpose of predicting BMI from the GRS. In the 
second stage, we fit a logistic model regressing case-control sta-
tus on the predicted values of BMI from the first-stage, adjusted 
for the estimated residuals from the first stage to account for the 
uncertainty in the predicted values of BMI. The first- and second-
stage models were also adjusted for age, as well as for the first four 
principal components that reflected the population structure to 
control for population stratification. The coefficient from the sec-
ond-stage regression is the effect of the instrumental variable for 
BMI (ie, the GRS per 1 kg/m2 increase in predicted BMI) on EAC/
BE. We used the F-statistic from the first-stage regression to assess 
the strength of the instrument (F>10 indicates sufficient strength 
to ensure the validity of the instrumental variable method) (22). 
For comparison, we present the estimates for the BMI-EAC and 
BMI-BE associations derived from multivariable logistic regres-
sion (“conventional epidemiologic analyses”). We compared the 
effect estimate from the instrumental variable analysis with that 
from the conventional epidemiologic analysis using the Durbin 
form of the Durbin-Wu-Hausman statistic (23). Rejection of the 
null hypothesis (ie, risk estimates for BMI from both analyses are 
equal) indicates that the estimate from conventional epidemiologic 
analysis may be confounded or biased. Statistical significance was 
determined at P = .05, and all tests for statistical significance were 
two-sided. Analyses were performed using Stata 12.0 (StataCorp, 
College Station, TX).
results
Compared with control patients, EAC case patients were older and 
more likely to be male, to have ever smoked, had GER symptoms, 
and used acid suppressant medications (Table 2). Similarly, BE case 
patients were more likely to have ever had GER symptoms and 
used acid suppressant medications than control patients.
Conventional Epidemiologic Analyses
On average, EAC (men, mean  =  28.4, standard deviation 
[SD] = 5.1; women, mean = 27.7, SD = 5.9) and BE case patients 
(men, mean = 28.8, SD = 4.8; women, mean = 29.4, SD = 6.2) had 
statistically significantly higher BMI than control patients (men, 
mean = 27.0, SD = 4.4; women, mean = 27.0, SD = 5.6). Among con-
trol patients, the prevalence of obesity was 19% and 23% among 
men and women, respectively, compared with 30% of men and 
women with EAC, and 35% of men and 42% of women with BE. 
We found strong associations between age, GER, acid suppressant 
medications, and BMI among the control patients (Table 3), sug-
gesting likely confounding with case-control status. On multivari-
able analysis (Table 4), EAC risk increased by 6% (95% CI = 1.05 
to 1.08), and BE risk increased by 4% (95% CI = 1.03 to 1.06) for 
every 1 kg/m2 increase in BMI.
Instrumental Variable Analyses
Control patients carried 15 to 39 BMI-increasing risk alleles 
(mean = 26.5, SD = 3.5), compared with 16 to 36 BMI-increasing 
risk alleles (mean = 26.9, SD = 3.4) in EAC case patients and 17 to 
38 BMI-increasing risk alleles (mean = 26.8, SD = 3.4) in BE case 
patients. The weighted GRS ranged from 1.66 to 5.50 (mean = 3.72, 
SD = 0.54) in control patients, 1.82 to 5.31 (mean = 3.79, SD = 0.53) 
in EAC cases and 2.20 to 5.36 (mean  =  3.77, SD  =  0.52) in BE 
case patients. In control patients and case patients, the GRS was 
normally distributed. Importantly, BMI increased with increas-
ing numbers of risk alleles in case patients and control patients 
(Figure 1), such that persons with higher scores had higher average 
BMIs. The GRS-BMI association was homogeneous across studies 
(Supplementary Figure 1, available online). In contrast to that seen 
for BMI, we found no consistent evidence of associations between 
the GRS and the covariates in Table 3. Therefore, these same risk 
factors are unlikely to confound the instrumental variable analyses 
evaluating the BMI-EAC and BMI-BE associations.
When we regressed BMI on the unweighted GRS among 
control patients, each additional BMI-increasing risk allele from 
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the risk score was associated with a 0.16 kg/m2 (95% CI  =  0.11 
to 0.22) increase in BMI. The GRS was a strong instrument for 
BMI (F-statistic = 31.4). In the instrumental variable (IV) analysis 
(Table 4), we found that a 1 kg/m2 increase in BMI was associated 
with a 16% increase in risk of EAC (IV OR = 1.16, 95% CI = 1.01 
to 1.33). There was no evidence that the effect estimate from the 
instrumental variable analysis differed from the effect estimate in the 
conventional epidemiologic analysis (Pdifference = .21). When we used 
the weighted GRS, the IV-OR estimate was moderately higher than 
the conventional epidemiologic analysis estimate (Pdifference = .05).
In the instrumental variable analysis of BE, there was a 12% 
increase in risk associated with a 1 kg/m2 increase in BMI (IV-
OR = 1.12, 95% CI = 1.00 to 1.25). We found a similar effect using 
the weighted GRS. The estimates from the instrumental variable 
analyses of BE did not differ from the conventional epidemiologic 
analysis estimate (unweighted, Pdifference = .61; weighted, Pdifference = .47).
The estimates were unchanged when we adjusted the instru-
mental variables models by potential confounders of the conven-
tional epidemiologic analysis, or when we analyzed only those with 
complete genotype, BMI, and covariate data.
To determine whether the effect of BMI on EAC and BE was 
modified by sex, we conducted stratified analyses (Table  4). In 
instrumental variable analysis among men, we found a statistically 
significant association between BMI and EAC. The association was 
weaker and not statistically significant among women; however, 
the confidence intervals overlapped with those for men. The risk 
estimates for BE were similar for men and women. None of these 
sex-specific ORs was statistically significantly different from those 
from conventional epidemiologic analyses.
Discussion
Epidemiological studies have previously implicated obesity in 
the etiology of BE (10) and EAC (9), as well as breast, colorectal, 
pancreatic, kidney, and gallbladder cancers (24). Conversely, obe-
sity is inversely related to lung cancer and esophageal squamous 
cell carcinoma (25). However, inferring causality between obesity 
and cancer from analysis of observational data presents substan-
tial challenges. Mendelian randomization is one method used to 
strengthen causal inference but has been underutilized in cancer 
Table 2. Characteristics of the study population
Characteristics
Population  










patients vs BE  
P*
Age, y, mean (SD) 61.7 (11.1) 63.9 (10.4) <.001 61.0 (12.2) .05
Sex <.001 .01
 Male 1705 (78.6) 883 (88.4) 1547 (75.1)
 Female 464 (21.4) 116 (11.6) 514 (24.9)
Highest level of education <.001 .01
 Less than high school 469 (21.6) 355 (35.5) 338 (16.4)
 High school or more 1696 (78.2) 633 (63.4) 1522 (73.9)
 Missing 4 (0.2) 11 (1.1) 201 (9.7)
Body mass index, kg/m2 <.001 <.001
 <25 787 (36.3) 246 (24.6) 429 (20.8)
 25–29.99 944 (43.5) 457 (45.8) 881 (42.8)
 ≥30 438 (20.2) 296 (29.6) 751 (36.4)
 mean (SD) 27.0 (4.7) 28.3 (5.2) 29.0 (5.2)
Cumulative smoking history, pack-years <.001 .18
 Never smoker 883 (40.7) 254 (25.4) 690 (33.5)
 ≤ 15 379 (17.5) 153 (15.3) 341 (16.6)
 15.01–30 319 (14.7) 148 (14.8) 236 (11.4)
 30.01–50 313 (14.4) 200 (20.0) 214 (10.4)
 >50 245 (11.3) 159 (15.9) 192 (9.3)
 Missing 30 (1.4) 85 (8.5) 388 (18.8)
Frequency of heartburn/acid reflux <.001 <.001
 Never 952 (43.9) 302 (30.2) 439 (21.3)
 Ever 1125 (51.9) 687 (68.8) 1430 (69.4)
 Missing 92 (4.2) 10 (1.0) 192 (9.3)
Frequency of use of aspirin or nonaspirin 
NSAIDs
.26 .50
 Never 808 (37.2) 379 (37.9) 497 (24.1)
 Ever 1027 (47.4) 438 (43.8) 665 (32.3)
 Missing 334 (15.4) 182 (18.2) 899 (43.6)
Ever use of acid suppressant 
medications
<.001 <.001
 Never 1345 (62.0) 361 (36.1) 372 (18.0)
 Ever 417 (19.2) 319 (31.9) 1500 (72.8)
 Missing 407 (18.8) 319 (31.9) 189 (9.2)
* P value from chi-square tests for categorical variables and Student t tests for continuous variables. Missing categories were excluded from comparison tests. 
BE = Barrett’s esophagus; EAC = esophageal adenocarcinoma; NSAIDs = nonsteroidal anti-inflammatory drugs; SD = standard deviation.
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research to date. Using genetic variants as instrumental variables 
for BMI, we examined the BMI-EAC and BMI-BE associations 
without the limitations of confounding or bias that can affect self-
reported estimates from observational studies. Since the genotype 
effect on BMI levels is inferred to represent lifetime BMI, the risk 
estimates reflect the effect of lifetime exposure to higher BMI. We 
found that elevated BMI was associated with increased risk of EAC 
and BE. The findings from the instrumental variable analysis con-
firm that obesity is independently associated with EAC and BE. 
Importantly, these findings also suggest that obesity may confer 
greater risk than previously reported (9,10).
The three fundamental relationships underlying the Mendelian 
randomization framework are: genotype–risk factor, risk factor–out-
come, and genotype-outcome. Assuming that three key assumptions 




Unweighted genetic  
risk score
Weighted genetic risk 
score
P*Mean (SD) Mean (SD) P* Mean (SD)
Age, β on linear regression -0.0279 (-0.046, -0.010) .002 0.0032 (-0.010, 0.017) .64 0.0008 (-0.001, 0.003) .45
Sex .78 .88 .66
 Male 27.02 (4.39) 26.53 (3.46) 3.73 (0.55)
 Female 26.95 (5.62) 26.56 (3.73) 3.72 (0.53)
Highest level of education .48 .04 .02
 Less than high school 27.14 (4.95) 26.83 (3.45) 3.77 (0.51)
 High school or more 26.97 (4.60) 26.46 (3.54) 3.71 (0.54)
 Missing 26.42 (4.24) 25.25 (3.20) 3.53 (0.49)
 Cumulative smoking history,  
 pack-years
.08 .35 .52
 Never smoker 26.88 (4.51) 26.37 (3.44) 3.71 (0.53)
 ≤15 26.62 (4.53) 26.75 (3.40) 3.76 (0.52)
 15.01–30 27.45 (4.59) 26.65 (3.56) 3.72 (0.53)
 30.01–50 27.03 (4.97) 26.54 (3.72) 3.74 (0.55)
 >50 27.44 (5.12) 26.74 (3.64) 3.74 (0.58)
 Missing 27.07 (5.04) 26.21 (3.81) 3.67 (0.58)
Frequency of heartburn / acid 
reflux
<.001 .28 .79
 Never 26.46 (4.30) 26.63 (3.50) 3.73 (0.53)
 Ever 27.32 (4.85) 26.46 (3.57) 3.72 (0.55)
 Missing 28.81 (5.45) 26.67 (3.20) 3.72 (0.49)
Frequency of use of aspirin or 
non-aspirin NSAIDs
.002 .02 .07
 Never 26.53 (4.29) 26.36 (3.45) 3.70 (0.53)
 Ever 27.19 (4.69) 26.73 (3.53) 3.74 (0.53)
 Missing 27.58 (5.41) 26.40 (3.65) 3.74 (0.56)
Ever use of acid suppressant 
medications
<.001 .94 .71
 Never 26.90 (4.63) 26.54 (3.51) 3.72 (0.54)
 Ever 28.40 (5.25) 26.55 (3.56) 3.73 (0.53)
 Missing 25.94 (3.80) 26.52 (3.54) 3.74 (0.52)
* P value from Student t test or analysis of variance. Missing categories were excluded from comparison tests. NSAIDs = nonsteroidal anti-inflammatory drugs.
Table 4. Comparison of conventional epidemiologic and instrumental variable associations between body mass index and risks of esopha-




Unweighted genetic risk score: 
IV-adjusted OR (95% CI) P†
Weighted genetic risk score: 
IV-adjusted OR (95% CI) P†
EAC
 All 1.06 (1.05 to 1.08) 1.16 (1.01 to 1.33) .21 1.23 (1.06 to 1.43) .05
 Men 1.07 (1.05 to 1.09) 1.22 (1.02 to 1.46) .15 1.31 (1.07 to 1.60) .05
 Women 1.04 (1.00 to 1.08) 1.03 (0.80 to 1.33) .96 1.13 (0.87 to 1.46) .47
BE
 All 1.04 (1.03 to 1.06) 1.12 (1.00 to 1.25) .61 1.13 (1.01 to 1.28) .47
 Men 1.05 (1.03 to 1.08) 1.11 (0.96 to 1.29) .81 1.15 (0.96 to 1.36) .58
 Women 1.03 (1.00 to 1.06) 1.11 (0.95 to 1.30) .64 1.10 (0.95 to 1.28) .72
* Adjusted for age (continuous), sex, education (less than high school, high school, or more), pack-years of smoking (never smoker, ≤15, 15.01–30, 30.01–50, 
>50 pack-years), gastroesophageal reflux symptoms (never, ever), acid suppressant medication use (never, ever), and NSAID use (never, ever). BE = Barrett’s 
esophagus; CI = confidence interval; EAC = esophageal adenocarcinoma; IV = instrumental variable. OR = odds ratio.
† P value from Durbin-Wu-Hausman test. All statistical tests were two-sided.
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are satisfied, the outcomes from the instrumental variable analysis 
will be unconfounded, unbiased estimates for the effect of obe-
sity on EAC and BE. We firstly assume that the genetic variants 
selected for analysis are associated with EAC and BE only through 
their association with BMI. Thus, we assume that they do not have 
a direct effect on EAC or BE. While it is unlikely that one or more 
pleiotropic SNPs in the GRS will reduce the causal implications of 
BMI calculated from the GRS, we are unable to directly test this 
assumption and it is thus possible that our IV estimates for the BMI 
associations are a combination of the BMI-outcome and the direct 
genotype-outcome effects. The second assumption is that the vari-
ants are associated with BMI. In particular, Mendelian randomiza-
tion requires a strong instrument for analysis (13). We used the 
top-performing SNPs from an external study, which we also dem-
onstrated were strongly associated with BMI in our large dataset. 
Given that the genetic risk score was a strong instrument for BMI in 
our study (F-statistic >>10), power and bias from weak instruments 
are unlikely to have seriously affected the results. We also satisfied 
the final assumption of the Mendelian randomization method, that 
the genetic risk scores are independent of potential confounders.
Case-control and cohort studies have reported statistically 
significant associations between BMI and risk of EAC and BE 
(9,10,26–33). The results of our conventional epidemiologic analy-
ses differ somewhat from a prior analysis of BEACON BE stud-
ies (10). That analysis utilized a two-stage meta-analytic approach; 
however, as we needed to pool genetic data, the current study 
used a different design and a somewhat different study popula-
tion. In these observational studies, the high correlation between 
BMI and multiple other environmental and lifestyle factors means 
that adequate control for all potential confounding may not have 
been possible. The inherent value of the Mendelian randomization 
approach is not in any greater specificity of exposure measurement, 
but that the exposure is assigned at conception, and therefore can-
not be confounded by subsequent environmental exposures. The 
higher risk estimates found in our instrumental variable analyses 
indicate that the estimates obtained from multivariable regression 
methods may underestimate the true BMI effect, possibly because 
of confounding and/or misclassification and reporting errors, or 
overadjustment in the context of intermediate variables, which may 
bias the risk estimate towards the null (34). Misclassification of self-
reported BMI may have biased our IV estimates away from the 
null. However, the bias is likely to be minimal, because measure-
ment error has been shown to be small and inconsequential for 
rare, binary outcomes such as EAC and BE (35,36).
GER is the primary risk factor for EAC and BE, and people who 
are obese experience GER symptoms more frequently (37). While 
studies of EAC and BE have adjusted for GER symptoms in mul-
tivariable analysis of BMI, it is impossible to exclude residual con-
founding because symptom history is imperfectly correlated with 
the occurrence of GER, and reporting can be compromised by 
treatment history. Other issues for interpretation of conventional 
analyses arise. Firstly, GER may be an intermediary on the causal 
pathway between obesity and neoplasia, in which case adjusting 
for GER symptoms may actually bias the true risk estimate (34). 
Secondly, conventional analyses are based on the participant’s BMI 
at one time point and thus may be subject to misclassification and 
reporting errors (eg, tall men under-report height and short men 
over-report height, and women under-report weight) (38,39). 
Thirdly, early stages of cancer may result in weight loss, and so 
BMI values taken from within this latent period may introduce 
bias because of reverse causation. As the latent period for BMI is 
unknown, a measure that reflects typical lifetime BMI may limit 
such bias.
Our analyses using the Mendelian randomization approach 
do not suffer from any of these sources of error, and thus provide 
the strongest evidence to date that obesity is a risk factor for BE 
and EAC, which operates independently of other factors that also 
inflate risk. The mechanisms remain largely unknown. There is 
an emerging body of evidence that visceral (as opposed to subcu-
taneous) fat is particularly important for promoting esophageal 
neoplasia (40–42), with adipokines (such as leptin) or proinflam-
matory cytokines (such as insulin-like growth factors) proposed as 
possible mediators. However, as the 29 SNPs are associated with 
BMI and not waist-to-hip ratio, the observed associations reflect 
the effects of total adiposity on risks of BE and EAC, suggesting 
that there may be an alternative mechanism underlying these asso-
ciations that does not relate to visceral adiposity. Unfortunately, we 
had too few participants with waist-to-hip ratio data (377 control 
patients, 746 BE case patients) to perform a Mendelian randomiza-
tion study to detect the independent effects of central vs overall 
obesity. Exploring these possible pathways and other mechanisms 
is an area of ongoing inquiry.
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